Treatment of lysosomal storage disorders

1. A method of treating a lysosomal storage disease in a mammal, said method comprising:

administering to said mammal an effective amount of a molecular tweezers that is capable of inhibiting protein aggregation, wherein said effective amount is an amount effective to slow the progression, or stop, or reverse protein accumulation/aggregation associated with said lysosomal storage disease, and/or said effective amount is an amount effective to ameliorate one or more symptoms of the pathology associated with said lysosomal storage disease and/or to reduce neurodegeneration and/or neuro-inflammation associated with said lysosomal storage disease;

wherein said lysosomal storage disease is Sanfilippo syndrome, and said method is effective to reactivate autophagic flux in the neurons of the mammal.

2. The method of claim 1 , wherein said effective amount is an amount effective to delay the onset, or to slow, or to stop, or to reverse progression of a pathology associated with said lysosomal storage disease.

3. The method of claim 1 , wherein said administration is before appearance of symptoms in said mammal and said mammal is identified as having the lysosomal storage disease by the presence of a genetic marker for said lysosomal storage disease.

4. The method of claim 1 , wherein said amelioration of one or more symptoms comprises a reduction of neuroinflammation and/or slowing, stopping, or reversing progression of neuro-inflammation.

5. The method of claim 4 , wherein a reduction of neuroinflammation and/or slowing, stopping, or reversing progression of neuro-inflammation is characterized by a reduction in one or more markers of neuroinflammation, wherein said marker(s) of neuroinflammation are selected from the group consisting of Iba1 (marker of microglial activation), GFAP (marker for astrocytic response), TNF-alpha, interleukins, and TGF-beta.

6. The method of claim 1 , wherein said method is effective to slow, or to stop, or to reverse neuronal loss (neurodegeneration) in said mammal.

7. The method of claim 1 , wherein said method is effective to reduce memory deficit, and/or to reduce abnormal lysosome size and/or number of abnormal sized lysosomes in said mammal.

8. The method of claim 1 , wherein said molecular tweezers is a molecular tweezers according to any one of formulas I to IV:

or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, wherein:

X 1 and X 2 are both O;

A alone, or A combined with X 1 , forms a substituent selected from the group consisting of phosphate, hydrogen phosphate, alkylphosphonate, arylphosphonate, alkylphosphamide, arylphosphamide, sulfate, hydrogen sulfate, alkylcarboxylate, and

B alone, or B combined with X 2 , forms a substituent selected from the group consisting of phosphate, hydrogen phosphate, alkylphosphonate, arylphosphonate, alkylphosphamide, arylphosphamide, sulfate, hydrogen sulfate, alkylcarboxylate and

 and

each of R 1 , R 2 , R 3 , and R 4 is, independently, selected from the group consisting of H, Cl, Br, I, OR, NR 2 , NO 2 , CO 2 H, and CO 2 R 5 , wherein R 5 is alkyl, aryl or H, or

R 1 and R 2 combine to form an aliphatic or aromatic ring, and/or

R 3 and R 4 combine to form an aliphatic or aromatic ring.

9. The method of claim 8 , wherein A and B are independently selected from the group consisting of

wherein A and B are optionally the same.

10. The method of claim 8 , wherein A and B are independently selected from the group consisting of

and —(CH 2 ) n —CO 2 − , where R 5 is alkyl or H; n ranges from 1 to 10, and Ar is aryl, where A and B are optionally the same.

11. The method of claim 8 , wherein said molecular comprises a compound according to a formula selected from the group consisting of:

12. The method of claim 1 , wherein said method is effective to rescue a memory deficit in said mammal.